Structured evidence table for Nicotinamide Riboside Exercise Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Nicotinamide Riboside Exercise Randomized Trial | Observational associations between dietary patterns and reduced dementia risk have prompted investigations of dietary bioactives (DBs) as cognitive nutraceuticals. | 2 | Kumari A (2026) | Dietary Bioactives in Alzheimer's Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies. |
| Nicotinamide Riboside Exercise Randomized Trial | Findings are synthesized qualitatively; no formal meta-analysis or risk of bias assessment was conducted. | 2 | Kumari A (2026) | Dietary Bioactives in Alzheimer's Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies. |
| Nicotinamide Riboside Exercise Randomized Trial | Cannabinoids improved behavioral symptoms but showed no measurable cognitive effects. | 2 | Kumari A (2026) | Dietary Bioactives in Alzheimer's Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies. |
| Nicotinamide Riboside Exercise Randomized Trial | Methods: This critical narrative review examines interventional trials for nine prominent DBs relevant to AD: docosahexaenoic acid (DHA), curcumin, resveratrol, epigallocatechin gallate (EGCG), nicotinamide riboside (NR), tricaprilin, vitamin E (α-tocopherol), cannabinoids, and NIC5-15 (D-pinitol). | 2 | Kumari A (2026) | Dietary Bioactives in Alzheimer's Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies. |
| Nicotinamide Riboside Exercise Randomized Trial | Importantly, while elevated intraocular pressure (IOP) is a well-established risk factor and the only available treatment target, it is neither necessary nor sufficient for the development of glaucoma, as evidenced by the existence of normal-tension glaucoma and the observation that many patients continue to progress despite achieving target IOP levels. | 3 | Hui Flora (2026) | Vitamins and nutraceuticals in glaucoma research |
| Nicotinamide Riboside Exercise Randomized Trial | It is estimated that the number of individuals affected by glaucoma will continue to rise, with substantial socioeconomic impact due to vision loss and associated disability.Age is the most prominent risk factor, but genetic predisposition, vascular dysregulation, and systemic metabolic dysfunction have also been implicated in disease susceptibility and progression. | 3 | Hui Flora (2026) | Vitamins and nutraceuticals in glaucoma research |
| Nicotinamide Riboside Exercise Randomized Trial | Studies suggest that up to 28% of retinal ganglion cells may be lost before early visual field defects become apparent.Advances in imaging, home-based visual field monitoring, and artificial intelligence-assisted analysis are being developed to improve early detection and risk stratification, but challenges remain in predicting individual disease trajectories. | 3 | Hui Flora (2026) | Vitamins and nutraceuticals in glaucoma research |
| Nicotinamide Riboside Exercise Randomized Trial | 1 2 , Glaucoma is a common neurodegenerative disease characterized by the degeneration of retinal ganglion cells and their axons, leading to characteristic structural changes at the optic nerve head and corresponding visual field loss. | 3 | Hui Flora (2026) | Vitamins and nutraceuticals in glaucoma research |
Source documents